Published • loading... • Updated
Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC
Inhibrx will present interim Phase 2 results comparing INBRX-106 plus pembrolizumab with pembrolizumab alone, and the webcast will remain available for 60 days.
- On Monday, May 11, 2026, Inhibrx Biosciences will host a live webcast at 5:30 a.m. Pacific Time to provide interim results from the HexAgon study.
- The HexAgon study evaluates the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, tested in combination therapy versus monotherapy in first-line patients with metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma.
- Utilizing Inhibrx's proprietary single-domain antibody platform, INBRX-106 is designed to achieve high-order receptor clustering necessary for robust T-cell activation and survival, addressing limitations of traditional bivalent antibody approaches.
- Investors may join the presentation via the web or by dialing the conference line using ID 1841482 for access.
- Following the event, the webcast will remain accessible for 60 days, while Inhibrx will update its corporate presentation through the Events and Presentations section of its website.
Insights by Ground AI
12 Articles
12 Articles
Coverage Details
Total News Sources12
Leaning Left0Leaning Right0Center7Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
